One of Asia’s largest integrated private healthcare groups, IHH Healthcare, and IBA (Ion Beam Applications S.A., EURONEXT), the world’s leading provider of proton therapy solutions for the treatment of cancer, announce today that they have signed a contract for the installation of a small single-room proton therapy system, Proteus®ONE*, at IHH flagship hospital in Singapore. For IBA, the contract is worth between 35 and 40 million euros (SGD 55 and 65 million).
IHH chose the IBA Proteus®ONE solution following a thorough selection procedure. The Proteus®ONE solution, IBA’s most recent Pencil Beam Scanning (PBS) technology, isocenter volumetric imaging (Cone Beam CT) capabilities, and the structure that will house the proton therapy facility are all covered by the deal. A different agreement governs the facility’s long-term operation and upkeep. The facility has started its operations and is open for patients to register.

Modern radiation therapy known as proton therapy has attracted a lot of interest in the field of oncology. It employs charged protons to precisely target cancer cells with the least amount of harm to normal tissues surrounding the tumor. Proton therapy has been popular in Southeast Asia, especially in Singapore, which is regarded for having a high-quality healthcare system. This development gives cancer patients in the area hope and better treatment alternatives.
Delivering highly targeted radiation to tumors is one of the main benefits of proton treatment, which lowers the chance of adverse effects and long-term difficulties. This is especially important when treating tumors that are close to essential organs or when treating children because radiation exposure must be kept to a minimum.
Singapore is home to cutting-edge proton therapy facilities that are outfitted with cutting-edge technology and highly qualified medical staff. These facilities, such the National Cancer Centre Singapore and the Singapore Proton Therapy Centre, provide complete cancer care and work in conjunction with prestigious worldwide organizations to guarantee the best standards of care.
For cancer patients, the availability of proton treatment in Singapore has changed everything. It offers patients with difficult-to-treat cancers new hope by delivering an alternative to conventional radiation therapy and surgery. Additionally, Singapore’s healthcare system’s interdisciplinary approach guarantees that patients receive individualized treatment programs that may combine therapies like surgery, chemotherapy, and proton therapy to meet their unique needs.
Additionally, Singapore’s proactive approach to research and innovation helps to develop proton treatment on a constant basis. The nation makes investments in clinical trials and joint research initiatives, enhancing its experience and understanding in this specialized field.
In conclusion, proton therapy has transformed the way that cancer is treated in Singapore by giving patients a precise and powerful tool to fight tumors. Singapore is at the vanguard of this ground-breaking therapy, providing new opportunities for cancer patients not only in the nation but also in the larger region, thanks to its cutting-edge facilities and dedication to research.